Abdel-Fatah, Broom RJ, Lu J, Moseley PM, Huang B, Li L, Liu S, Chen L, Ma RZ, Cao W, Wang X, Li Y, Perry JK, Aleskandarany M, Nolan CC, Rakha EA, Lobie PE, Chan SYT, Ellis IO, Hwang LA, Lane DP, Green AR, Liu DX,19 (2019). SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment (2019). B J Cancer, 120(7), 728-745. doi: 10.1038/s41416-019-0405-x. Epub 2019 Feb 28.

Ng S, Juang YC, Chandramohan A, Kaan HYK, Sadruddin A, Yuen TY, Ferrer FJ, Lee XEC, Xi L, Johannes CW, Brown CJ, Kannan S, Aronica PG, Berglund N, Verma CS, Liu LJ, Stoeck A, Sawyer TK, Partridge AW, Lane DP (2019). De-risking drug discovery of intracellular targeting peptides: screening strategies to eliminate false-positive hits. BioRXiv, doi:

Pradhan MR, Siau JW, Kannan S, Nguyen MN, Ouaray Z, Kwoh CK, Lane DP, Ghadessy F, Verma CS (2019). Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket. Nucleic Acids Research, 47(4), 1637–1652. doi: 10.1093/nar/gky1314.

Xue Y, Barker N, Hoon S, He P, Thakur T, Abdeen SR, Maruthappan P, Ghadessy FJ, Lane DP (2019). Bortezomib Stabilizes and Activates p53 in Proliferative Compartments of both Normal and Tumor Tissues In Vivo. Cancer Res, 79(14), 3595-3607. doi: 10.1158/0008-5472.CAN-18-3744. Epub 2019 May 28.

Partridge AW, Kaan HYK, Juang YC, Sadruddin A, Lim S, Brown CJ, Ng S, Thean D, Ferrer F, Johannes C, Yuen TY, Kannan S, Aronica P, Tan YS, Pradhan MR, Verma CS, Hochman J, Chen S, Wan H, Ha S, Sherborne B2, Lane DP, Sawyer TK (2019). Incorporation of putative helix-breaking amino acids in the design of novel stapled peptides: Exploring biophysical and cellular permeability properties. Molecules, 24(12). pii: E2292. doi: 10.3390/molecules24122292.

 Koh XY, Koh XH, Hwang LA, Ferrer FJ, Rahmat SAB, Lama D, Lane DP (2019). Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase . Oncogene. doi: 10.1038/s41388-019-0946-8. [Epub ahead of print].

Ong JFM, Goh HC, Lim SC, Pang LM, Chin JSF, Tan KS, Liang ZX, Yang L, Glukhov E, Gerwick WH, Tan LT (2019). Integrated Genomic and Metabolomic Approach to the Discovery of Potential Anti-Quorum Sensing Natural Products from Microbes Associated with Marine Samples from Singapore. Mar Drugs, 17(1), 72. doi: 10.3390/md17010072.

Sana B, Chee SMQ, Wongsantichon J, Raghavan S, Robinson RC, Ghadessy FJ (2019). Development and structural characterization of an engineered multi-copper oxidase reporter of protein-protein interactions. J Biol Chem, 294(17), 7002-7012. doi: 10.1074/jbc.RA118.007141. Epub 2019 Feb 15.

Yuen TY, Brown CJ, Xue Y, Tan YS, Ferrer Gago FJ, Lee XE, Neo JY, Thean D, Kaan HYK, Partridge AW, Verma CS, Lane DP, Johannes CW (2019). Stereoisomerism of stapled peptide inhibitors of the p53-Mdm2 interaction: an assessment of synthetic strategies and activity profiles. Chem Sci, 10(26). 10(26):6457-6466. doi: 10.1039/c9sc01456j. eCollection 2019 Jul 14.

Yuri Frosi, Rachael Usher, Dawn Thean Gek Lian, David P. Lane, Christopher J. Brown (2019). Monitoring flux in signaling pathways through measurements of 4EBP1-mediated eIF4F Complex assembly. BMC Biology, 17(1):40, doi: 10.1186/s12915-019-0658-0.

Lama D, Liberatore AM, Frosi Y, Nakhle J, Tsomaia N, Bashir T, Lane DP, Brown CJ, Verma CS, Auvin, S. (2019). Structural insights reveal arecognition feature for tailoring hydrocarbon stapled-peptides againstthe eukaryotic translation initiation factor 4E protein. S. Chem Sci., 10(8), 2489-2500.


D Spiegelberg, AC Mortensen, S Lundsten, CJ Brown, DP Lane, M Nestor (2018). The MDM2/MDMX-p53 antagonist PM2 radiosensitizes wild-type p53 tumors. Cancer Research, 78 (17), 5084-5093.

Ho T and Lane DP. (2018). Guardian of Genome Editing. CRISPR J., 1, 258-260.

Sawyer TK, Partridge AW, Kaan HYK, Juang YC, Lim S, Johannes C, Yuen TY, Verma C, Kannan S, Aronica P, Tan YS, Sherborne B, Ha S, Hochman J, Chen S, Surdi L, Peier A, B, Dandliker PJ, Brown CJ, Ng S, Ferrer F, Lane DP (2018). Macrocyclic α helical peptide therapeutic modality: A perspective of learnings and challenges. Bioorg Med Chem., 26 (10), 2807-2815.

Costeira-Paulo J, Gault J, Popova G, Ladds MJGW, van Leeuwen IMM, Sarr M, Olsson A, Lane DP, Laín S, Marklund EG, Landreh M. (2018). Lipids Shape the Electron Acceptor-Binding Site of the Peripheral Membrane Protein Dihydroorotate Dehydrogenase. Cell Chem Biol. 2018 Jan 17. pii: S2451-9456(17)30461-0. doi: 10.1016/j.chembiol.2017.12.012. [Epub ahead of print]

Hwang LA, Phang BH, Liew OW, Iqbal J, Koh XH, Koh XY, Othman R, Xue Y, Richards AM, Lane DP, Sabapathy K. (2018). Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision MedicineCell Rep. 2018 Jan 2;22(1):299-312.


Zheng S, Koh XY, Goh HC, Rahmat SAB, Hwang LA and Lane DP. (2017). Inhibiting p53 Acetylation Reduces Cancer Chemotoxicity. Cancer Research, 77, 4342-4354.

Thean D, Ebo JS, Luxton T, Lee XC, Yuen TY, Ferrer FJ, Johannes CW, Lane DP, Brown CJ. Enhancing (2017). Enhancing Specific Disruption of Intracellular Protein Complexes by Hydrocarbon Stapled Peptides Using Lipid Based Delivery. Sci Rep., 11;7 (1), 1763.

 Cheok CF, Lane DP. Cold Spring Harb Perspect Med. (2017). Exploiting the p53 Pathway for Therapy.  2017 Mar 1;7(3). Review

Goh HC, Sobota RM, Ghadessy FJ, Nirantar S. (2017). Going native: Complete removal of protein purification affinity tags by simple modification of existing tags and proteases. Protein Expr Purif. 2017 Jan;129:18-24.

 Tan BX, Liew HP, Chua JS, Ghadessy FJ, Tan YS, Lane DP, Coffill CR. (2017). Anatomy of Mdm2 and Mdm4 in evolution. J Mol Cell Biol. 2017 Jan 10. [Epub ahead of print] Review.


Siau JW, Coffill CR, Zhang WV, Tan YS, Hundt J, Lane D, Verma C, and Ghadessy F. (2016). Functional characterization of p53 pathway components in the ancient metazoan Trichoplax adhaerens. Sci Rep., 6, 33972. 

Xue Y, Raharja A, Sim W, Wong ES, Rahmat SA, Lane DP. (2016). The hot-spot p53R172H mutant promotes formation of giant spermatogonia triggered by DNA damage. Oncogene. 2016 Nov 21. doi: 10.1038/onc.2016.374. [Epub ahead of print]

Wei SJ, Chee S, Yurlova L, Lane D, Verma C, Brown C, Ghadessy F. (2016). Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides.  Oncotarget. 2016 Apr 4. doi: 10.18632/oncotarget.8572. [Epub ahead of print]

Tan YS, Lane DP, Verma CS. (2016). Stapled peptide design: principles and roles of computation. Drug Discov Today. 2016 Jun 18. pii: S1359-6446(16)30230-6.

Coffill CR, Lee AP, Siau JW, Chee SM, Joseph TL, Tan YS, Madhumalar A, Tay BH, Brenner S, Verma CS, Ghadessy FJ, Venkatesh B, Lane DP. (2016). The p53-Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humansGenes Dev. 2016 Feb 1;30(3):281-92.

Kannan S, Lane DP, Verma CS. (2016). Long range recognition and selection in IDPs: the interactions of the C-terminus of p53. Sci Rep. 2016; 6: 23750.


 Geng J, Goh WL, Zhang C, Lane DP, Liu B, Ghadessy G, Tan YN. (2015).  A highly sensitive fluorescent light-up probe for real-time detection of the endogenous protein target and its antagonism in live cells. Journals of Materials Chemistry B, 2015, 3, 5933-5937.

Chua JS, Liew HP, Guo L, Lane DP. (2015). Tumor-specific signaling to p53 is mimicked by Mdm2 inactivation in zebrafish: insights from mdm2 and mdm4 mutant zebrafish.  Oncogene. 2015 Mar 9. doi: 10.1038/onc.2015.57. [Epub ahead of print]

Tan BX, Brown CJ, Ferrer FJ, Yuen TY, Quah ST, Chan BH, Jansson AE, Teo HL, Nordlund P, Lane DP. (2015). Assessing the Efficacy of Mdm2/Mdm4-Inhibiting Stapled Peptides Using Cellular Thermal Shift Assays. Sci Rep., 5, 12116.


L Li, DSW Ng, W-C Mah, FF Almeida, SA Rahmat, VK Rao, SC Leow, F Laudisi, MT Peh, AM Goh, JSY Lim, GD Wright, A Mortellaro, R Taneja, F Ginhoux, CG Lee, PK Moore, DP Lane. (2014). A unique role for p53 in the regulation of M2 marcophage polarisation. Cell Death Differ. 2014 Dec 19. doi: 10.1038/cdd.2014.212. [Epub ahead of print]

Kian Hoe Khoo, Chandra S. Verma & David P. Lane (2014). Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014 Feb 28;13(3):217-36.


Lama D, Quah ST, Verma CS, lakshminarayanan R, Beuerman RW, Lane DP, Brown CJ (2013). Rational optimization of conformational effects induced by hydrocarbon staples in peptides and their binding interfaces. Sci Rep., 13 (3), 3451.

Brown CJ, Quah ST, Jong J, Goh AM, Chiam PC, Khoo KH, Choong ML, Lee MA, Yurlova L, Zolghadr K, Joseph TL, Verma CS, Lane DP (2013). Stapled peptides with improved potency and specificity that activate p53. ACS Chem Biol., 15;8 (3), 506-12.

Tan, B.X., Khoo, K.H., Lim, T.M., Lane, D.P. (2013). High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia.  Oncotarget. 2013 Nov 22. 

Mondal, A.M., Horikawa, I., Pine, S.R., Fujita, K., Morgan, K.M., Vera, E., Mazur, S.J., Appella, E., Vojtesek, B., Blasco, M.A., Lane, D.P., Harris, C.C. (2013). p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. J Clin Invest. 2013 Dec 2;123(12):5247-57.

Wong, J.S., Warbrick, E., Vojtesk, B., Hill, J., Lane, D.P. (2013). Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth Oncotarget. 2013 Jul;4(7):1019-36.

Tao, T., Shi, H., Guan, Y., Huang, D., Chen, Y., Lane, D.P., Chen, J., Peng, J. (2013). Def defines a conserved nucleolar pathway that leads p53 to proteasome-independent degradation. Cell Res. 2013 Jan 29.

2012 and earlier

Guo L, Liew HP, Camus S, Goh AM, Chee LL, Lunny DP, Lane EB, Lane DP (2012).   Oncogene. 2012 Oct 15.

Coffill, C.R., Muller, P.A., Oh, H.K., Neo, S.P., Hogue, K.A., Cheok, C.F., Vousden, K.H., Lane, D.P., Blackstock, W.P., Gunaratne, J. (2012). Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasionEMBO Rep. 2012 Jun 29: 13(7):638-44.  

Muller, P.A., Trinidad, A.G., Timpson, P., Morton, J.P., Zanivan, S., van den Berghe, P.V., Nixon, C., Karim, S.A., Caswell, P.T., Noll, J.E., Coffill, C.R., Lane, D.P., Sansom, O.J., Neilsen, P.M., Norman, J.C., Vousden, K.H. (2012). Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene. 2013 Mar 7;32(10):1252-65.

Goh, A.M., Lim, C.Y., Chiam, P.C., Li, L., Mann, M.B., Mann, K.M., Menendez, S. and Lane, D.P. (2012). Using targeted transgenic reporter mice to study promoter-specific p53 transcriptional activity. Proc Natl Acad Sci U S A. 109(5), 1685-90.  

Lane, D.P., Madhumalar, A., Lee, A.P., Tay, B.H., Verma, C., Brenner, S, and Venkatesh B. (2011). Conservation of all three p53 family members and Mdm2 and Mdm4 in the cartilaginous fish. Cell Cycle. 10(24), 4272-9.  

Dastidar, S.G., Raghunathan, D., Nicholson, J., Hupp, T.R., Lane, D.P. and Verma, C.S. (2011). Chemical states of the N-terminal "lid" of MDM2 regulate p53 binding: simulations reveal complexities of modulation Cell Cycle. 10(1), 82-9.  

See, H.Y. and Lane, D.P. (2010).  A novel unstructured scaffold based on 4EBP1 enables the functional display of a wide range of bioactive peptides. J Mol Biol. 404(5), 819-31.  

 Cheok, C.F., Kua, N., Kaldis, P. and Lane, D.P. (2010). Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cell Death Differ. 17(9), 1486-500

Lane, D.P., Cheok, C.F., Brown, C., Madhumalar, A., Ghadessy, F.J. and Verma, C. (2010). Mdm2 and p53 are highly conserved from placozoans to man. Cell Cycle. 9(3), 540-547.

Wan, K.F., Wang, S., Brown, C.J., Yu, V.C., Entzeroth, M., Lane, D.P. and Lee, M.A. (2009). Differential scanning fluorimetry as secondary screening platform for small molecule inhibitors of Bcl-XL.Cell Cycle. 8(23), 3943-52.

Brown, C.J., Dastidar, S.G., See, H.Y., Coomber, D.W., Ortiz-Lombardía, M., Verma, C. and Lane, D.P. (2009). Rational Design and Biophysical Characterization of Thioredoxin-Based Aptamers: Insights into Peptide Grafting. J Mol Biol. 395(4), 871-83.

Brown, C.J., Verma, C.S., Walkinshaw, M.D. and Lane, D.P. (2009). Crystallization of eIF4E complexed with eIF4GI peptide and glycerol reveals distinct structural differences around the cap-binding site. Cell Cycle. 8, 1905-1911.

Chen, J., Ng, S.M., Chang, C., Zhang, Z., Bourdon, J.C., Lane, D.P. and Peng, J. (2009). p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev. 2009. 23: 278-90

Lain, S., Hollick, J.J., Campbell, J., Staples, O.D., Higgins, M., Aoubala, M., McCarthy, A., Appleyard, V., Murray, K.E., Baker, L., Thompson, A., Mathers, J., Holland, S.J., Stark, M.J.R., Pass, G., Woods, J., Lane, D.P. and Westwood, N.J. (2008). Discovery, in vivo activity and mechanism of action of a small-molecule p53 activator.  Cancer Cell. 2008. 13:454-63.

Lee, K.C., Goh, W.L., Xu, M., Kua, N., Lunny, D., Wong, J.S., Coomber, D., Vojtesek, B., Lane, E.B. and Lane, D.P. (2008). Detection of the p53 response in zebrafish embryos using new monoclonal antibodies. Oncogene. 2008. 27 (5): 629-40

Dey, A., Wong, E.T., Cheok, C.F., Tergaonkar, V. and Lane, D.P. (2008). R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ. 2008. 15: 263-73.

Cheok CF, Dey A, Lane DP. (2007). Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.  Mol Cancer Res. 2007. 5(11):1133-45.

Stevenson, L.F., Sparks, A., Allende-Vega, N., Xirodimas, D.P., Lane, D.P. and Saville, M.K. (2007). The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J. 2007. 26:976-86.

Chen, J., Ruan, H., Ng, S.M., Gao, C., Soo, H.M., Wu, W., Zhang, Z., Wen, Z., Lane, D.P. and Peng, J. (2005). Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish. Genes Dev. 2005. 19:2900-11.

Bourdon, J.C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D.P., Saville, M.K. and Lane, D.P. (2005). p53 isoforms can regulate p53 transcriptional activity.  Genes Dev. 2005. 19:2122-37.

Kontopidis, G., Wu, S.Y., Zheleva, D.I., Taylor, P., McInnes, C, Lane, D.P., Fischer, P.M. and Walkinshaw, M.D. (2005). From the Cover: Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design. Proc Natl Acad Sci U S A. 2005. 102(6):1871-6.

Xirodimas, D.P., Saville, M.K., Bourdon, J.C., Hay, R.T. and Lane, D.P. (2004). Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell. 2004. 9:83-97.

Bottger, A., Bottger, V., Sparks, A., Liu,, W.L., Howard, S. and Lane, D.P.  (1997). Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol. 1997. 7:860-869.

Hupp, T.R., Sparks, A. and Lane, D.P. (1995). Small peptides activate the latent sequence specific DNA binding function of p53.  Cell. 1995. 83:237-245.

Lu, X. and Lane, D.P. (1993). Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell. 1993. 75:765-778. 

Hall, P.A., McKee, P.H., Menage, H du P., Dover, R. and Lane, D.P. (1993). High levels of p53 protein in UV irradiated normal human skin. Oncogene. 1993. 8:203-207.

Lane, D.P. (1992). Cancer - p53, Guardian of the Genome. Nature. 1992. 358:15-16.

Hupp, T.R., Meek, D.W., Midgley, C.A. and Lane, D.P. (1992). Regulation of the DNA binding function of p53. Cell. 1992. 71:875-886.

Bartek, J. Bartkova, J. Vojtesek, B. Staskova, Z. Lukas, J. Rejthar, A. Kovarik, J. Midgley, C.A. Gannon, J.V. and Lane, D.P. (1991). Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.  Oncogene. 1991. 6:1699-1703.

Iggo, R. Gatter K.G. Bartek, J., Lane, D. and Harris, A.L. (1990). Increased expression of mutant forms of the p53 oncogene in primary lung cancer.  Lancet. 1990. 335:675-679.

Yewdell, J.W., Gannon, J.V. and Lane, D.P. (1986). Monoclonal antibody analysis of p53 expression in normal and transformed cells.  J.Virol. 1986. 59:444-452.

Lane, D.P. and Crawford, L.V. (1979). SV40 T antigen is bound to a host protein in V40 transformed cells. Nature. 1979. 278:261-263.

Please click here for a full list of David Lane's publications.

Check here for David Lane's full Pubmed entry